Clinical Edge Journal Scan

Presence of PsA increases prevalence of anxiety and depression in psoriasis


 

Key clinical point: Patients with concomitant psoriasis and psoriatic arthritis (PsA) vs only psoriasis were more likely to experience mild depressive symptoms and anxiety, with the association being mediated by pain.

Major finding: Among patients with psoriasis, those with vs without PsA had a higher prevalence of mild depressive symptoms (Hospital Anxiety and Depression Scale [HADS] score ≥8: adjusted odds ratio [aOR] 1.64; P = .037) but not severe depressive symptoms (HADS score ≥ 11) and a high prevalence of mild-to-severe anxiety (HADS score ≥ 8: aOR 1.51; P = .038 and HADS score ≥ 11; aOR 1.62; P = .037). Pain mediated the effect of PsA on depression and anxiety.

Study details: The data of 707 British Association of Dermatologists Biologic and Immunomodulators Register participants (540 with psoriasis and 167 with both psoriasis and PsA) were analyzed.

Disclosures: This study was funded by the UK National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre. Some authors declared serving as speakers or advisory board members, or receiving honoraria, funding, compensation, research grants, or consulting fees from several sources.

Source: Lada G et al. Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin Health Dis. 2022;e149 (Jul 6). Doi: 10.1002/ski2.149

Recommended Reading

NAFLD strongly correlated with psoriasis, PsA; risk linked to severity
MDedge Rheumatology
Questionnaire for patients with psoriasis might identify risk of axial involvement
MDedge Rheumatology
Rapid and sustained improvement in diverse PsA manifestations with guselkumab
MDedge Rheumatology
PsA: Long-term efficacy and safety of ixekizumab with or without csDMARD
MDedge Rheumatology
PsA: Sustained improvement in patient-reported outcomes with bimekizumab
MDedge Rheumatology
PsA: Risankizumab improves patient-reported outcomes in phase 3 trial
MDedge Rheumatology
Guselkumab leads to meaningful and consistent improvement in general health outcomes in PsA
MDedge Rheumatology
PsA: Long-term retention, efficacy, and safety of secukinumab in real world
MDedge Rheumatology
Reluctance of biologic initiation in systemic-therapy-naive PsA patients receiving apremilast
MDedge Rheumatology
PsA: Clinical and therapeutic features associated with early vs late onset of psoriasis
MDedge Rheumatology